; and (B) a disclosure of any potential conflicts of interest that may exist regarding any official of the Food and Drug Administration who was involved in the decision to approve the drug prior to the Commissioner's final decision under subsection (a); and (2) at the request of the Committee on Health, Education, Labor, and Pensions of the Senate or the Committee on Energy and Commerce of the House of Representatives, testify before that committee regarding the Commissioner's decision to approve the opioid drug against the recommendation of the advisory committee. (c) Prohibition on marketing A drug approved as described in subsection (a) shall not be introduced or delivered for introduction into interstate commerce until the report described in subsection (b)(1) has been submitted to Congress. (d) Scope of advisory committee review Section 106(a)(1)(A) of the Comprehensive Drug and Recovery Act of 2016 ( Public Law 114–198 ) is amended— (1) by inserting , or supplement to an application, after application each place such term appears; and (2) by striking of a new and inserting for .